Dr. Paul Billings is the new chief medical officer of Omicia, an Oakland, Calif.-based company that provides genome analysis technology for research, diagnostic and clinical applications.
Billings, who will also serve on Omicia's scientific advisory board, joins the company at a time when it is moving more toward individualized medicine enabled by the understanding of the genetic basis of disease, drug response and health. Today, its products are in use at more than 300 academic and clinical facilities worldwide.
“Genomics is moving to the clinic, and Paul is one of the industry leaders that will guide us in this new world of genomic and individualized medicine,” Omicia CEO Mike Aicher said in a release. “We have made huge strides this year securing financing from new investors, appointing additional high profile board members, and working with critical clients who quickly see the interpretive value Omicia delivers. All of this sets the stage for us to continue rapid growth, attracting new customers and collaborators.”
Billings comes to Omicia from Life Technologies, where he also served as CMO. He is also a founder of CBR Systems for cordblood stem cell banking and GeneSage, provider of genomic information and online testing.Follow Rachel Landen on Twitter: @MHrlanden